Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is BUTENAFINE HYDROCHLORIDE, with a corresponding US DMF Number 19551.
Remarkably, this DMF maintains an Active status since its submission on June 27, 2006, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of June 25, 2013, and payment made on January 23, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II